In HelloNation, Chiropractic Expert Dr. Kevin D. Trembush Discusses Why Chiropractic Treatment Plans Require Multiple Visits

The article argues that meaningful chiropractic improvement typically requires a multi-visit treatment plan rather than a single adjustment, especially for chronic mechanical imbalances. It outlines a three-stage progression—initial pain relief, corrective alignment, and spinal stabilization—emphasizing gradual tissue and joint adaptation through repetition. No financial metrics, companies, or market catalysts are provided, and the piece appears to be informational/marketing content rather than a tradable news event.

Analysis

This is effectively brand-content, not a catalyst. The only market mechanism here is a potential read-through to recurring-visit business models in cash-pay wellness/MSK care, but that is too diffuse to matter for public equities without evidence of traffic, conversion, or reimbursement changes. For CRMT and ZCBD, the linkage is essentially nil; any move in either name would be noise rather than a fundamentals-based repricing.

The second-order issue is that this kind of messaging can inflate expectations around patient retention and lifetime value, but the economics only show up if visit frequency rises and then sticks for multiple quarters. That means the relevant horizon is months to years, not days. The near-term risk is more about promotional overreach than demand creation: if claims are perceived as medical marketing rather than measurable outcomes, there is no durable benefit and potentially some scrutiny.

Contrarian view: the consensus may over-interpret wellness education as a demand signal. The reality is that the article is trying to justify more sessions, not prove better outcomes, so the burden of proof stays on utilization data. Falsifiers would be unchanged repeat-visit rates, flat same-store sales, or no improvement in patient retention metrics from any chiropractic/MSK operator supposedly benefiting from this theme.

Key Decisions for Investors

• No trade in CRMT or ZCBD on this item; expected impact is de minimis and not investable.
• Do not initiate options or a pair trade from this article alone; wait for hard utilization data (repeat visits, retention, same-store sales) before expressing any view.
• Set a watch alert on USPH and other musculoskeletal service names for evidence of higher revisit cadence over the next 1-2 quarters; only then does the recurring-revenue thesis become actionable.
• If this theme later appears alongside verified volume growth, consider a long MSK services / short broad healthcare ETF expression, but treat it as a conditional trade, not a present recommendation.